A Phase 2 interventional study of LIB003 in Hypercholesterolemia, sponsored by LIB Therapeutics LLC. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-02.
Sponsored by LIB Therapeutics LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 379 studies in Hypercholesterolemia with a site in United States — 32 open to participants now, 42 under way, 11 of them phase 3. Hypercholesterolemia · United States.
Among the 379 studies in Hypercholesterolemia with a site in United States, this one is the 285th largest by enrollment of the 347 interventional ones that give a count, is one of 6 that started in 2019, is one of 66 in phase 2, and was the 282nd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →32 of the 379 studies in Hypercholesterolemia with a site in United States are open now. Recruiting first, the newest first:
Verve Therapeutics, Inc. · Sites in United States
Ages 18–70
AstraZeneca · Sites in United States, Australia, Canada and 1 more country
Ages 18–130
AstraZeneca · Sites in United States, Bulgaria, Canada and 8 more countries
Ages 18–130
Novartis Pharmaceuticals · Sites in United States
Ages 18–75
Midwest Center for Metabolic and Cardiovascular Research · Sites in United States
Ages 18–74 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
379 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 72 · Phase 3 106 · Phase 4 33
First in 1976; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 120 across the 347 interventional studies, 260 across the 31 observational. Of the 319 that completed or were terminated, 161 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
208 of 379 have an industry lead sponsor. The 10 most frequent:
LIB Therapeutics LLC is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.
LIB Therapeutics LLC has 8 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
18 of the studies in Hypercholesterolemia with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07619118Phase 3AstraZenecaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia | 2027-05-28 |
| NCT07619131Phase 3AstraZenecaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. | 2027-07-30 |
| NCT06960655Brigham and Women's HospitalImproving Lipid Optimization Quality and Treatment Options in ASCVD | 2026-11-30 |
| NCT02694094Johns Hopkins UniversityImpact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 379 studies in Hypercholesterolemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the longer term safety, tolerability, and LDL C lowering efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W)
To assess the longer term safety, tolerability, immunogenicity, PK, PD and LDL C lowering efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W) in patients on stable maximally tolerated statins with or without ezetimibe who completed the phase 2 dose ranging trial LIB003-002
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LIB003
Drug: LIB003
300 mg SC Q4W
Also known as: lerodalcibep
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
safety and tolerability will be based on the incidence and severity of treatment emergent adverse events
Time frame: 52 weeks
Percent Change in LDL-C at 52 Weeks
percent change in serum LDL-C from baseline at 52 weeks
Time frame: 52 weeks
4 clinical centers in USA, recruitment from patients completing a phase 2 dose ranging trial (LIB003-002)
| Milestone | LIB003 (Lerodalcibep) |
|---|---|
| Started | 32 |
| Completed | 26 |
| Not completed | 6 |
| Withdrew: Relocated out of region | 3 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Adverse event | 1 |
safety and tolerability will be based on the incidence and severity of treatment emergent adverse events
| Participants | LIB003 (Lerodalcibep) |
|---|---|
| SAE | 3 |
| ISRs | 5 |
percent change in serum LDL-C from baseline at 52 weeks
| percentage from baseline | LIB003 (Lerodalcibep) |
|---|---|
| Percent Change in LDL-C at 52 Weeks | 64.1 ± 17.4 |
Collected over 52 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LIB003 (Lerodalcibep) | 0/32 (0%) | 3/32 (9.4%) | 28/32 (87.5%) |
| Event | LIB003 (Lerodalcibep) |
|---|---|
| supraventricular tachycardiaCardiac disorders | 1/32 |
| small bowel obstructionGastrointestinal disorders | 1/32 |
| worsening of uterine fibroidsReproductive system and breast disorders | 1/32 |
| Event | LIB003 (Lerodalcibep) |
|---|---|
| Other Adverse EventGeneral disorders | 28/32 |
| Other (Not Including Serious) Adverse Events were not monitored/assessed using specific Adverse EvenSkin and subcutaneous tissue disorders | 3/32 |
Subjects with CVD or high risk for CVD on maximally tolerated statin completing 12 week Phase 2 LIB003-002 dose ranging trial
| Age, Continuous(years) | LIB003 |
|---|---|
| Mean | 63.1 (32 to 80) |
| Sex: Female, Male(Participants) | LIB003 |
|---|---|
| Female | 20 |
| Male | 12 |
| Race/Ethnicity, Customized(Participants) | LIB003 |
|---|---|
| White | 25 |
| African-American | 7 |
| Region of Enrollment(Participants) | LIB003 |
|---|---|
| United States | 32 |
| BMI(kg/m^2) | LIB003 |
|---|---|
| Mean | 30.08 (21.7 to 37.8) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2019 to primary completion in Apr 2020, 13 months.
Results were first posted in Feb 2022, 1 year 10 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 13 months is above that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lerodalcibep
LIB Therapeutics LLC